3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
3
Phase 3
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Genitourinary
1
Endocrine
1
CNS
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Zoledronic Acid
23
Bevacizumab
13
nilotinib
12
Docetaxel
12
Paclitaxel
11
Everolimus
11
Letrozole
10
Imatinib Mesylate
10
Capecitabine
10
Erlotinib Hydrochloride
9
Drug Therapy
9
Carboplatin
9
pegfilgrastim
8
enzalutamide
8
Trastuzumab
7
Oxycodone
7
Nivolumab
7
Imiquimod
7
Gemcitabine
7
Epoetin Alfa
7
icotinib
6
Rituximab
6
Prednisone
6
Pemetrexed
6
Oxaliplatin
6
Leuprolide
6
Fulvestrant
6
Diclofenac
6
Dexamethasone
6
Cisplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 4
×
INDUSTRY
×
gadoterate meglumine
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled
NCT01806740
2019-08-08
DCE-MRI
Guerbet
Phase 4
Terminated
37 enrolled
12 charts
NCT02034708
2016-12-30
REMIND
Guerbet
Phase 4
Completed
279 enrolled
9 charts